Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Strata Critical Medical (SRTAW) Current Leases (2020 - 2025)

Historic Current Leases for Strata Critical Medical (SRTAW) over the last 6 years, with Q3 2025 value amounting to $654000.0.

  • Strata Critical Medical's Current Leases fell 8537.57% to $654000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $654000.0, marking a year-over-year decrease of 8537.57%. This contributed to the annual value of $682000.0 for FY2024, which is 8575.31% down from last year.
  • Strata Critical Medical's Current Leases amounted to $654000.0 in Q3 2025, which was down 8537.57% from $3.5 million recorded in Q2 2025.
  • In the past 5 years, Strata Critical Medical's Current Leases registered a high of $4.8 million during Q4 2023, and its lowest value of $333000.0 during Q2 2021.
  • Its 5-year average for Current Leases is $2.7 million, with a median of $3.4 million in 2022.
  • Per our database at Business Quant, Strata Critical Medical's Current Leases skyrocketed by 71229.84% in 2023 and then crashed by 8575.31% in 2024.
  • Quarter analysis of 5 years shows Strata Critical Medical's Current Leases stood at $438000.0 in 2021, then soared by 667.58% to $3.4 million in 2022, then skyrocketed by 42.39% to $4.8 million in 2023, then tumbled by 85.75% to $682000.0 in 2024, then decreased by 4.11% to $654000.0 in 2025.
  • Its last three reported values are $654000.0 in Q3 2025, $3.5 million for Q2 2025, and $3.4 million during Q1 2025.